Journal
DIGESTIVE DISEASES AND SCIENCES
Volume 45, Issue 7, Pages 1462-1464Publisher
KLUWER ACADEMIC/PLENUM PUBL
DOI: 10.1023/A:1005588911207
Keywords
Crohn's disease; mesalamine; probiotics; relapses; Saccharomyces boulardii
Categories
Ask authors/readers for more resources
The possible role of Saccharomyces bouldardii, a nonpathogenic yeast with beneficial effects on the human intestine, in the maintenance treatment of Crohn's disease has been evaluated. Thirty-two patients with Crohn's disease in clinical remission (CDAI < 150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5% of patients receiving mesalamine alone and in 6.25% of patients in the group treated with mesalamine plus the probiotic agent, Our results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn's disease. However, in view of the product's cost, further controlled studies are needed to confirm these preliminary data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available